[ad_1]
NeoGenomics (NASDAQ:NEO) unit Inivata reported optimistic information for its RaDaR liquid biopsy check in head and neck squamous cell carcinoma (HNSCC).
Within the LIONESS examine, blood samples taken from 17 sufferers with stage 3-4B, p16-negative HNSCC who acquired curative-intent main surgical therapy have been examined utilizing RaDaR to detect circulating tumor DNA (ctDNA) as proof of minimal residual illness (MRD) and recurrence pre- and post-surgery.
The corporate mentioned all sufferers had detectable ctDNA previous to surgical procedure (100% medical detection).
In monitoring after surgical procedure, ctDNA was detected in 5 sufferers at low ranges, in step with earlier research using RaDaR in breast and lung most cancers.
The corporate added that ctDNA was detected previous to development in all 5 sufferers with medical recurrence, with lead instances forward of medical affirmation starting from 108 to 253 days.
Within the remaining 12 sufferers there was no recurrence detected, indicating a 100% medical specificity of the RaDaR assay and confirming post-operative tumor clearance.
“The assay confirmed exceptionally excessive sensitivity, detecting ctDNA in each HNSCC affected person who went on to recur, which together with its specificity demonstrates the potential of RaDaR to determine HNSCC sufferers at an elevated danger of relapse, enabling earlier intervention and customized remedy planning,” mentioned Inivata’s Chief Medical Officer David Eberhard.
The info from the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) examine have been revealed within the British Journal of Most cancers.
[ad_2]
Source link